Oscotec files IND application to US FDA

Published: 2009-03-23 06:58:00

Updated: 2009-03-23 06:58:00

Oscotec Inc. said it has filed an application of its osteoarthritis medicine OCT-1547 to the US Food and Drug Administration and EMCA in Europe, it was announced on March 19.

OCT-1547 inhibits the differentiation and activity of osteoclasts by blocking the signal transduction necessary for ost...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK